Patrizia Giannatempo: The benefit of adjuvant pembrolizumab with extended follow-up 45 months

Patrizia Giannatempo shared a post on X:

“The AMBASSADOR trial confirms the benefit of adjuvant pembrolizumab with extended fu 45 months:

• regardless of PD-L1 status
•  lower tract.

Andrea Apolo – exceptional as always.”

Source: Patrizia Giannatempo/X

Patrizia Giannatempo is a Medical Oncology Consultant specializing in urological cancers at the National Cancer Institute (INT) in Milan, Italy. She serves as the principal investigator for several academic trials focused on urothelial, testicular, and penile cancers.